Top

Published in:

01-03-2018 | Original Scientific Report

Risk Factors for Unresectable Recurrence After Up-Front Surgery for Colorectal Liver Metastasis

Authors: Daisuke Hokuto, Takeo Nomi, Satoshi Yasuda, Takahiro Yoshikawa, Kohei Ishioka, Takatsugu Yamada, Takahiro Akahori, Kenji Nakagawa, Minako Nagai, Kota Nakamura, Shinsaku Obara, Hiromichi Kanehiro, Masayuki Sho

Published in: World Journal of Surgery | Issue 3/2018

Abstract

Background

There is no clear evidence that preoperative chemotherapy for resectable colorectal liver metastasis (CRLM) is superior to up-front surgery (UFS). The aim of this study was to identify the risk factors associated with poor prognosis after UFS for CRLM.

Methods

Data about consecutive patients with CRLM who underwent liver resection at Nara Medical University Hospital between January 2000 and December 2015 were retrieved from a prospective database. Recurrence that developed within 2 years after liver resection and could not be surgically resected was defined as unresectable recurrence (UR). Preoperative risk factors associated with UR after UFS were analyzed. Among the patients with the identified risk factors, the patients who were treated with UFS were compared with those who received preoperative chemotherapy via propensity score-matching analysis.

Results

There were 167 patients treated with UFS, and 71 of them developed UR (the UR group). The overall survival (OS) rate of the UR group was significantly worse than that of the non-UR group (5-year survival rate: 3.8 vs. 66.8%, p < 0.001). Multivariate analysis identified a primary colorectal cancer N factor of N2–3 as a risk factor for UR (hazard ratio 2.72, p = 0.004). Propensity score-matching analysis demonstrated that among patients with N2–3 primary colorectal cancer the post-initial treatment OS of the patients treated with UFS was significantly worse than that of the patients who received preoperative chemotherapy (5-year survival rate: 11.1 vs. 30.0%, p = 0.046).

Conclusions

Patients with CRLM with a primary colorectal cancer N factor of N2–3 should be considered for preoperative chemotherapy.

Rees M, Tekkis PP, Welsh FK et al (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247:125–135CrossRefPubMed

Quan D, Gallinger S, Nhan C et al (2012) The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery 151:860–870CrossRefPubMed

Jegatheeswaran S, Mason JM, Hancock HC, Siriwardena AK (2013) The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg 148:385–391CrossRefPubMed

Brudvik KW, Kopetz SE, Li L et al (2015) Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 102:1175–1183CrossRefPubMed

Hasegawa K, Saiura A, Takayama T et al (2016) Adjuvant oral uracil–tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial. PLoS ONE 11:e0162400CrossRefPubMedPubMedCentral

Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976–4982CrossRefPubMed

Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26:4906–4911CrossRefPubMed

Chua TC, Saxena A, Liauw W et al (2010) Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17:492–501CrossRefPubMed

Adam R, Haller DG, Poston G et al (2010) Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer–an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol 21:1579–1584CrossRefPubMed

10.

Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016CrossRefPubMedPubMedCentral

11.

Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215CrossRefPubMed

12.

Khan AZ, Morris-Stiff G, Makuuchi M (2009) Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg 16:137–144CrossRefPubMed

13.

Karoui M, Penna C, Amin-Hashem M et al (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1–7CrossRefPubMedPubMedCentral

14.

Welsh FK, Tilney HS, Tekkis PP et al (2007) Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 96:1037–1042CrossRefPubMedPubMedCentral

15.

Hokuto D, Nomi T, Kawaguchi C et al (2016) The Administration of Celecoxib as an Analgesic after Liver Resection Is Safe. Dig Surg 34:108–113CrossRefPubMed

16.

Hokuto D, Nomi T, Yamato I et al (2016) Impact of mechanical bowel preparation on postoperative outcomes after liver resection for patients with hepatocellular carcinoma: a single-center retrospective cohort study. Dig Surg 33:51–57CrossRefPubMed

17.

Hokuto D, Nomi T, Yamato I et al (2016) The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy. J Surg Oncol 114:959–965CrossRefPubMed

18.

Araujo R, Gonen M, Allen P et al (2013) Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. Ann Surg Oncol 20:4312–4321CrossRefPubMed

19.

Ayez N, van der Stok EP, Grunhagen DJ et al (2015) The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator. Eur J Surg Oncol 41:859–867CrossRefPubMed

20.

Khoo E, O’Neill S, Brown E et al (2016) Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB (Oxford) 18:485–493CrossRef

21.

Saiura A, Yamamoto J, Hasegawa K et al (2012) Liver resection for multiple colorectal liver metastases with surgery up-front approach: bi-institutional analysis of 736 consecutive cases. World J Surg 36:2171–2178. doi:10.1007/s00268-012-1616-y CrossRefPubMed

22.

Nanji S, Cleary S, Ryan P et al (2013) Up-front hepatic resection for metastatic colorectal cancer results in favorable long-term survival. Ann Surg Oncol 20:295–304CrossRefPubMed

Title: Risk Factors for Unresectable Recurrence After Up-Front Surgery for Colorectal Liver Metastasis
Authors: Daisuke Hokuto
Takeo Nomi
Satoshi Yasuda
Takahiro Yoshikawa
Kohei Ishioka
Takatsugu Yamada
Takahiro Akahori
Kenji Nakagawa
Minako Nagai
Kota Nakamura
Shinsaku Obara
Hiromichi Kanehiro
Masayuki Sho
Publication date: 01-03-2018
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 3/2018
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-017-4195-0

At a glance: The STEP trials

Springer Medicine

Risk Factors for Unresectable Recurrence After Up-Front Surgery for Colorectal Liver Metastasis

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Undiagnosed Primary Hyperparathyroidism and Recurrent Miscarriage: The First Prospective Pilot Study

Risk Factors for Central Neck Lymph Node Metastases in Micro- Versus Macro- Clinically Node Negative Papillary Thyroid Carcinoma

Acute Appendicitis: Still a Surgical Disease? Results from a Propensity Score-Based Outcome Analysis of Conservative Versus Surgical Management from a Prospective Database

In Response to: Ventilation in Trauma Patients: The First 24 h is Different!

Feasibility of Intraoperative Navigation for Liver Resection Using Real-time Virtual Sonography With Novel Automatic Registration System

Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA